{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":20,"n_cols":5,"rows_kept":20,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[13,2,13,3],[14,2,14,3],[18,2,18,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910144742103321"]
[null,null,"Autore",null,"Askari Arman T"]
[null,null,"Titolo",null,"Management strategies in antithrombotic therapy [[electronic resource] /] / by Arman Askari and Adrian W. Messerli"]
[null,null,"Pubbl/distr/stampa",null,"Chichester ; ; Hoboken, N.J., : John Wiley and Sons, c2007"]
[null,null,"ISBN",null,"1-282-34825-6"]
[{"$nulls":4},"9786612348259"]
[{"$nulls":4},"0-470-51813-8"]
[{"$nulls":4},"0-470-51814-6"]
[null,null,"Descrizione fisica",null,"1 online resource (372 p.)"]
[null,null,"Disciplina",null,"616.1/42"]
[null,null,"Soggetti",null,"Thrombolytic therapy"]
[{"$nulls":4},"Thrombosis - Treatment"]
[{"$nulls":4},"Fibrinolytic agents"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Thrombosis and antithrombotics in vascular disease -- Aspirin -- Thienopyridines, ticlopidine, and clopidogrel -- Platelet glycoprotein IIb/IIIa inhibitors -- Unfractionated heparin -- Low-molecular-weight heparins -- Direct thrombin inhibitors -- Fibrinolytic agents -- Acute ST-segment elevation myocardial infarction -- Acute coronary syndromes / non-ST-segment elevation myocardial infarction -- Anticoagulation strategies for patients undergoing percutaneous coronary intervention -- Venous thromboembolic disease -- Heparin-induced thrombocytopenia."]
[null,null,null,"Sommario/riassunto","Intravascular thrombus formation remains one of the most significant problems in cardiovascular medicine. It underlies the clinical presentation of acute coronary syndromes, including unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction. More and more individuals are stricken with an acute MI and undergo a percutaneous coronary intervention (PCI). Several reasons apply, including an increasingly aged population, the growing burden of chronic risk factors such as diabetes, obesity, sedentary behaviour, and improvements in e"]